Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL versus ETHRIL 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL versus ETHRIL 500.
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL vs ETHRIL 500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin ethylsuccinate is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation. Sulfisoxazole acetyl is a sulfonamide that inhibits dihydropteroate synthase, blocking folic acid synthesis.
Acetaminophen (paracetamol) is a central analgesic and antipyretic agent whose exact mechanism is not fully understood but is thought to involve inhibition of cyclooxygenase (COX) enzymes in the brain, primarily COX-2, and activation of descending serotonergic pathways. It has weak peripheral anti-inflammatory activity.
Erythromycin ethylsuccinate (400 mg) and sulfisoxazole acetyl (600 mg) per 5 mL suspension: 2-3 teaspoonfuls (10-15 mL) orally every 6 hours for 10-14 days. Maximum daily dose: 6 g sulfisoxazole.
500 mg orally every 6 hours as needed for pain. Maximum daily dose: 2000 mg.
None Documented
None Documented
Erythromycin: terminal half-life of 1.4-2.0 hours in adults; prolonged to 4-6 hours in anuria. Sulfisoxazole: half-life 4.5-7 hours in adults; increased in renal impairment. The combination's clinical context warrants dosing interval adjustments in renal dysfunction.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 6-12 hours in hepatic impairment or overdose.
Erythromycin ethylsuccinate is primarily excreted in bile (up to 80% as unchanged drug), with about 12-15% eliminated renally. Sulfisoxazole acetyl is renally excreted, with approximately 85% of the dose appearing in urine as acetylated and deacetylated metabolites. Fecal elimination accounts for less than 10% of sulfisoxazole.
Renal excretion of unchanged drug and glucuronide conjugate accounts for 90-95% of elimination; biliary/fecal elimination accounts for 5-10%.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic